INT20052

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1988
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 4.51
Pain Relevance 4.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (UGT1A1) endoplasmic reticulum (UGT1A1) enzyme binding (UGT1A1)
Anatomy Link Frequency
plasma 1
UGT1A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 28 100.00 Very High Very High Very High
Paracetamol 12 100.00 Very High Very High Very High
Buprenorphine 7 99.98 Very High Very High Very High
Endep 6 99.72 Very High Very High Very High
depression 5 88.40 High High
ischemia 2 85.96 High High
Bile 22 80.72 Quite High
Lamotrigine 1 74.72 Quite High
Nortriptyline 1 74.20 Quite High
Inflammation 7 72.24 Quite High
Disease Link Frequency Relevance Heat
Syndrome 17 98.60 Very High Very High Very High
Gallstones 30 98.56 Very High Very High Very High
Thalassemia 6 93.60 High High
Choledocholithiasis 8 92.60 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 302 92.56 High High
Respiratory Failure 1 89.36 High High
Hyperglycemia 5 88.40 High High
Sickle Cell Anemia 12 87.60 High High
Cv Unclassified Under Development 4 85.96 High High
Hyperbilirubinemia 1 84.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, marked reductions in UGT1A1 and UGT2B7 activities were observed in the presence of the herbal extracts using oestradiol and morphine as probe substrates, respectively.
Negative_regulation (reductions) of UGT1A1 associated with morphine
1) Confidence 0.58 Published 2007 Journal Xenobiotica Section Abstract Doc Link 17484515 Disease Relevance 0.07 Pain Relevance 0.44
Additionally, BUP inhibits NBUP glucuronidation (UGT1A1, 1A3, HLMs) and vice versa (UGT1A3).
Negative_regulation (inhibits) of UGT1A1 associated with endep and buprenorphine
2) Confidence 0.41 Published 2010 Journal Int. J. Legal Med. Section Abstract Doc Link 20111869 Disease Relevance 0.09 Pain Relevance 0.89
In those studies, raltegravir plasma levels were increased when coadministered with atazanavir, consistent with inhibition of UGT1A1.
Negative_regulation (inhibition) of UGT1A1 in plasma
3) Confidence 0.39 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504063 Disease Relevance 0.18 Pain Relevance 0
Atazanavir is a known inhibitor of UGT1A1, the primary pathway of clearance of raltegravir, and was selected to assess the greatest potential for increases in raltegravir pharmacokinetics (Mistry et al 2007).
Negative_regulation (inhibitor) of UGT1A1
4) Confidence 0.39 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504063 Disease Relevance 0.24 Pain Relevance 0
Each of these xenobiotics were shown to be a non-inhibitor of the high affinity morphine-UDPGT activity, or at least to have considerably lower affinity for this enzyme form(s) than morphine itself.
Negative_regulation (inhibitor) of morphine-UDPGT associated with morphine
5) Confidence 0.38 Published 1988 Journal Biochem. Pharmacol. Section Abstract Doc Link 3134892 Disease Relevance 0 Pain Relevance 0.89
Chloramphenicol, 4-hydroxybiphenyl, 4-methylumbelliferone, 1-naphthol and 4-nitrophenol were all shown to inhibit the low affinity morphine-UDPGT activity, but only chloramphenicol and 1-naphthol were competitive inhibitors.
Negative_regulation (inhibit) of morphine-UDPGT associated with morphine
6) Confidence 0.38 Published 1988 Journal Biochem. Pharmacol. Section Abstract Doc Link 3134892 Disease Relevance 0 Pain Relevance 0.85
Of these compounds, only digitoxigenin monodigitoxoside and 1-naphthol were found to cause significant inhibition of paracetamol UDPGT activity.
Negative_regulation (inhibition) of UDPGT associated with paracetamol
7) Confidence 0.37 Published 1990 Journal Biochem. Pharmacol. Section Abstract Doc Link 2116803 Disease Relevance 0 Pain Relevance 0.92
Similar results were obtained for tenofovir disoproxil fumarate, another protease inhibitor that is also known to inhibit UGT1A1.44
Negative_regulation (inhibit) of UGT1A1
8) Confidence 0.25 Published 2010 Journal Core evidence Section Body Doc Link PMC2899791 Disease Relevance 0.05 Pain Relevance 0
Bilirubin elevation on nilotinib may be due in part to nilotinib inhibition of UGT1A1 activity.
Negative_regulation (inhibition) of UGT1A1
9) Confidence 0.22 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC3000369 Disease Relevance 0.93 Pain Relevance 0
Atazanavir, a protease inhibitor, inhibits UGT1A1.
Negative_regulation (inhibits) of UGT1A1
10) Confidence 0.21 Published 2010 Journal Core evidence Section Body Doc Link PMC2899791 Disease Relevance 0.32 Pain Relevance 0
The highest prevalence of these complications occurs in patients with Gilbert's syndrome because of the combined effect of increased bilirubin production and reduced bilirubin-diphosphate-glucuronosyltransferase (UGT1-A1) enzyme activity [7,8].
Negative_regulation (reduced) of bilirubin-diphosphate-glucuronosyltransferase associated with syndrome
11) Confidence 0.06 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2964605 Disease Relevance 1.56 Pain Relevance 0.18
The highest prevalence of these complications occurs in patients with Gilbert's syndrome because of the combined effect of increased bilirubin production and reduced bilirubin-diphosphate-glucuronosyltransferase enzyme activity.
Negative_regulation (reduced) of bilirubin-diphosphate-glucuronosyltransferase associated with syndrome
12) Confidence 0.06 Published 2010 Journal BMC Gastroenterol Section Abstract Doc Link PMC2964605 Disease Relevance 1.08 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox